Vaxart Inc Stock Price, News & Analysis

Vaxart (OTCQX: VXRT) will host two investor webcasts in November 2025. Management will report third quarter 2025 financial results after market close on Thursday, November 13, 2025 and hold a conference call at 4:30 p.m. ET. A stockholder fireside chat is scheduled for Tuesday, November 18, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to answer shareholder questions.

Both events will be webcast on the company website and replayed afterward. Investors can call in using the provided domestic and international numbers for the Nov. 13 call, and may submit questions in advance to ir@vaxart.com or via the webcast portal.

Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.

Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.

Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025.

The presentation, titled “An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate”, is scheduled for Monday, October 20, 2025, 1:45 PM–3:00 PM ET in room B401-B402 and will be delivered by Nicholas J. Bennett, MBBChir, PhD.

Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.

The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.

Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced the withdrawal of its reverse stock split proposal. CEO Steven Lo emphasized that the company will maintain frequent stockholder communication while focusing on advancing their oral pill vaccine platform technology.

The decision comes after receiving constructive feedback from stockholders, with management expressing commitment to creating long-term value through their proprietary vaccine delivery platform development.

Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, has appointed W. Mark Watson as Lead Independent Director. Watson, a Certified Public Accountant with over 50 years of experience, including 40+ years at Deloitte, has served on Vaxart's Board since August 2022.

The company is implementing two significant governance changes: appointing Watson as Lead Independent Director and adopting a Director stock ownership policy to align Board interests with stockholders. Additionally, Vaxart is actively seeking stockholder approval for a reverse stock split, with voting deadline set for September 18, 2025, at 11:59 p.m. ET. The special stockholder meeting will be held virtually on September 19, 2025, at 8:30 a.m. PT.

Vaxart (OTCQX: VXRT) has reported promising Phase 1 data for its second-generation norovirus oral pill vaccine. The vaccine demonstrated a 25-fold increase in GII.4 fecal IgA response and a 10-fold increase in GI.I fecal IgA response over baseline with high-dose administration.

The second-generation constructs showed superior immunologic responses compared to first-generation versions, which previously demonstrated a 30% relative reduction in infection versus placebo in Phase 2b trials. The company's vaccine technology uniquely induces intestinal immunity, potentially offering stronger protection at the virus entry site.

With norovirus causing 685 million infections globally annually and representing a $10+ billion economic impact in the U.S., Vaxart is seeking partnerships to advance to Phase 2 trials by late 2025, with potential Phase 3 trials beginning in 2026.

Vaxart (NASDAQ:VXRT) announced the adjournment of its 2025 special meeting of stockholders to September 19, 2025. The meeting, which includes a critical reverse stock split proposal to maintain Nasdaq listing, was postponed to give shareholders more time to consider recent board changes, potential governance modifications, and upcoming company disclosures.

CEO Steven Lo emphasized the importance of maintaining Nasdaq listing for advancing the company's science and maximizing shareholder value. The virtual meeting will be accessible to stockholders of record as of July 29, 2025, who can vote until 11:59 p.m. ET on September 18, 2025.